BTIG Downgrades EPIRUS Biopharmaceuticals (EPRS) to Neutral

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. COIN
5. PINS
6. FSLR
7. SYK
8. DASH
9. GILD
10. SBUX

Go back to BTIG Downgrades EPIRUS Biopharmaceuticals (EPRS) to Neutral

Wedbush Downgrades EPIRUS Biopharmaceuticals (EPRS) to Neutral

May 11, 2016 6:58 AM EDT

Wedbush downgraded EPIRUS Biopharmaceuticals (NASDAQ: EPRS) from Outperform to Neutral with a price target of $2.00 (from $11.00) as the company shifts its business model to focus on biosimilars for rare diseases.

Analyst Heather Behanna commented, "Epirus is shifting its business model to... More

EPIRUS Biopharma (EPRS) Will Reallocate Resources to Focus on BOW080, BOW070 Development

May 9, 2016 4:01 PM EDT

EPIRUS Biopharmaceuticals, Inc. (Nasdaq: EPRS) announced reprioritization of the companys pipeline to focus exclusively on developing biosimilars for the treatment of rare diseases. This includes reallocating the Companys resources to focus on the development of BOW080 (eculizumab; reference... More